Reactivation of herpesviruses during COVID‐19: A systematic review and meta‐analysis
Reviews in Medical Virology · 2023-05 · 33 (3)
DOI: 10.1002/rmv.2437 ↗At a glance
Metaanalyse in Reviews in Medical Virology, published online on 2023-03-07. Written by Arman Shafiee and 7 co-authors. Institution: Clinical Research Development Unit, Alborz University of Medical Sciences, Karaj, Iran. Major MEDLINE topics: Herpesviridae Infections, Epstein-Barr Virus Infections, COVID-19, Herpesviridae. Cited 64 times so far (Crossref); 87 references.
Abstract (original language)
To provide a comprehensive systematic review and meta‐analysis regarding the cumulative incidence (incidence proportion) of human herpesvirus (HHV) reactivation among patients with coronavirus disease 2019 (COVID‐19), we searched PubMed/MEDLINE, Web of Science, and EMBASE up to 25 September 2022, with no language restrictions. All interventional and observational studies enrolling patients with confirmed COVID‐19 and providing data regarding HHV reactivation were included. The random‐effects model was used in the meta‐analyses. We included information from 32 studies. HHV reactivation was considered a positive polymerase chain reaction result taken at the time of COVID‐19 infection. Most of the included patients were severe COVID‐19 cases. The pooled cumulative incidence estimate was 38% (95% Confidence Intervals [CI], 28%–50%, I 2 = 86%) for herpes simplex virus (HSV), 19% (95% CI, 13%–28%, I 2 = 87%) for cytomegalovirus (CMV), 45% (95% CI, 28%–63%, I 2 = 96%) for Epstein‐Barr virus (EBV), 18% (95% CI, 8%–35%) for human herpesvirus 6 (HHV‐6), 44% (95% CI, 32%–56%) for human herpesvirus 7 (HHV‐7), and 19% (95% CI, 14%–26%) for human herpesvirus 8 (HHV‐8). There was no evidence of funnel plot asymmetry based on visual inspection and Egger's regression test for the results of HSV ( p = 0.84), CMV ( p = 0.82), and EBV ( p = 0.27) reactivation. In conclusion, the identification of HHV reactivation in severe COVID‐19 patients is helpful in the management of patients as well as the prevention of complications. Further research is required to elucidate the interaction between HHVs and COVID‐19. Systematic review registration: PROSPERO CRD42022321973.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Clinical Research Development Unit, Alborz University of Medical Sciences, Karaj, Iran.
- Student Research Committee, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Student Research Committee, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
- Dental Materials Research Center, Dental School, Islamic Azad University of Medical Sciences, Tehran, Iran.
- Department of Microbiology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
ORCID profiles: Mohammad Mobin Teymouri Athar, Sayed-Hamidreza Mozhgani
Cite
APA
Shafiee, A., Teymouri Athar, M. M., Amini, M. J., Hajishah, H., Siahvoshi, S., Jalali, M., Jahanbakhshi, B., & Mozhgani, S. H. (2023). Reactivation of herpesviruses during COVID‐19: A systematic review and meta‐analysis. Reviews in Medical Virology, 33(3). https://doi.org/10.1002/rmv.2437
Vancouver
Shafiee A, Teymouri Athar MM, Amini MJ, Hajishah H, Siahvoshi S, Jalali M, et al. Reactivation of herpesviruses during COVID‐19: A systematic review and meta‐analysis. Reviews in Medical Virology. 2023;33(3). doi:10.1002/rmv.2437
BibTeX
@article{Shafiee2023,
author = {Shafiee, Arman and Teymouri Athar, Mohammad Mobin and Amini, Mohammad Javad and Hajishah, Hamed and Siahvoshi, Sepehr and Jalali, Mehrsa and Jahanbakhshi, Bahar and Mozhgani, Sayed-Hamidreza},
title = {Reactivation of herpesviruses during COVID‐19: A systematic review and meta‐analysis},
journal = {Reviews in Medical Virology},
year = {2023},
volume = {33},
number = {3},
doi = {10.1002/rmv.2437}
}
EUVIMED